A chimeric antigenreceptor (CAR)-T cell therapy is a type of treatment in which a patient's Tcells, lymphocytes of a type produced or processed by the thymus gland andactively participating in the immune response, are modified to attack cancercells.
Increasing prevalenceof cancer is expected to boost growth of the global CAR-T cell therapy marketover the forecast period. For instance, according to the World HealthOrganization, around 18.1 million new cases and 9.6 million deaths wereregistered due to cancer worldwide in 2018. Moreover, increasing preference forgenetically engineered treatment approaches for the effective treatment ofvarious types of cancers is also expected to aid in growth of the market.
*The sample copy includes: Report Summary, Table of Contents, Segmentation,Competitive Landscape, Report Structure, Methodology.
Request a sample copy of thisreport: https://www.coherentmarketinsights.com/insight/request-sample/102
Increasing investmentsrelated to CAR-T cell therapy are expected to fuel growth of the global CAR-Tcell therapy market over the forecast period. For instance, in 2016, NovartisInternational AG invested around US$ 9 billion in R&D in CAR-T celltherapy. Other companies that are actively involved in R&D in CAR-T celltherapy for diffuse large B-cell lymphoma and relapsed/refractory acutelymphoblastic leukemia include Juno Therapeutics and Kite Pharma Inc.
Among regions, NorthAmerica is expected to hold dominant position in the global CAR-T cell therapymarket over the forecast period. This is owing to increasing prevalence ofcancer in the region. For instance, according to Fight Colorectal Cancer Organization,there will be an estimated 140,250 new cases of colorectal cancer in 2019 inthe U.S.
Europe is expected tofollow North America in terms of market share. However, conductingcountry-specific clinical trials across the region is expected to be a majorchallenge for growth of the market.
Among the types oftherapy, the CD 19-based therapy segment is expected to hold dominant positionin the global CAR-T cell therapy market over the forecast period. This is owingto increasing R&D related to CD 19 for the treatment of leukemia. Otherantigens such as CD 20 and CD 22 are also expected to witness significantgrowth.
Major players in themarket are focused on conducting clinical trials to expand their productportfolio. For instance, in February 2020, Precision BioSciences announced itsplan to initiate a clinical trial for its new CAR T-cell therapy candidate,PBCAR269A, for the treatment of relapsed or refractory multiple myeloma. ThePhase 1/2a trial (NCT04171843) is expected to begin enrolling eligible adultsin March at multiple U.S. sites.
BrowseResearch Report: https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102
Moreover, in March2020, Tessa Therapeutics received the U.S. Food and Drug Administration (FDA)’sRegenerative Medicine Advanced Therapy designation to its investigationalCD30-targeted CAR T-cell therapy for the treatment of relapsed or refractoryclassical Hodgkin’s lymphoma.
Key Takeaways
· Increasing prevalence of cancer toaugment growth of the global CAR-T cell therapy market over the forecast period
· North America is expected to account for58.3% of overall industry share in 2018
· CD 19 segment is expected to touch abillion dollar mark by 2023
· Major players operating in the globalCAR-T cell therapy market include, Novartis International AG, Kite Pharma, Inc.(Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio,Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc.,Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer,Inc., CARsgen Therapeutics, Ltd., and others.
Buy-Nowthis research report: https://www.coherentmarketinsights.com/insight/buy-now/102
About CoherentMarket Insights:
Coherent MarketInsights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
Contact Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent MarketInsights 1001 4th Ave,
# 3200 Seattle, WA98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
